PhRMA Moves To Vanquish FTC Rule Targeting Drugmakers

Law360, New York (February 10, 2014, 5:29 PM EST) -- The Pharmaceutical Research and Manufacturers of America on Friday urged a D.C. federal judge to vacate a Federal Trade Commission rule requiring pharmaceutical companies to report more exclusive patent licenses for antitrust approval under federal merger law, arguing that the agency lacks the authority to target specific sectors.

In a motion for summary judgment, the leading pharmaceutical trade group told the court that the November rule, which upped the reporting burden on its member companies, far exceeds the FTC's authority under the Hart-Scott-Rodino Act. That statute, according...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA v. FEDERAL TRADE COMMISSION


Case Number

1:13-cv-01974

Court

District Of Columbia

Nature of Suit

Administrative Procedure Act/Review or Appeal of Agency Decision

Judge

Beryl A. Howell

Date Filed

December 11, 2013

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.